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Abstract: PH46A is a single enantiomer and a member of the 1,2-indane dimer family. It has two
contiguous stereogenic centers with S,S configurations, one of which being a quaternary center,
which has been developed as a clinical candidate for the treatment of inflammatory and autoimmune
conditions. The current synthetic route to PH46A involves the generation of an unwanted enantiomer
(R,R)-7, thus reducing the final yield significantly. Therefore, we have investigated potential
alternatives to improve the efficiency of this synthesis. The first phase of the study has demonstrated
proof of principle for a chiral alkylation of ketone 3 using phase-transfer catalysis, providing a key
intermediate ketone (S)-4. The parent alkaloids required for the synthesis of PH46A, quinine or
cinchonidine, have also been identified. Promising enantiomeric excesses of up to 50% have been
achieved to date, and the use of an alternative substrate, unsaturated ketone 9, has also opened up
further avenues for optimisation in future studies. The second part of the study involved preliminary
screening the effects of a panel of hydrolase enzymes on (rac)-4 in order to identify a potential
chemo-enzymatic route to optimise the introduction of chirality into PH46A at early stage of the
synthesis. The hydrolase module has also yielded positive results; enzyme AH-46 with MtBE
providing a selectivity factor of 8.4 with enantiomeric excess of 77%. Overall, positive results were
obtained in this proof of concept study described herein. It is believed that conditions of both chiral
PTC alkylation and biocatalytic hydrolysis could be optimised to further enhance the selectivity and
improve the overall yield. This work is currently ongoing.
Keywords: bioactive indanes; PH46A; enantioselective; biocatalysis; hydrolases; phase-transfer
catalyst (PTC)
1. Introduction
The indane scaffold is a key moiety found in a range of biologically active naturally occurring
and synthetic molecules. During the course of our work, a novel indane scaffold was discovered,
which demonstrated potential treatment of inflammatory conditions, in particular Inflammatory Bowel
Disease (IBD) [1–6]. A lead first-in-class chiral molecule, PH46A, 6-(methylamino)hexane-1,2,3,4,5-
pentanol-4-(((1S,2S)-1-hydroxy-2,3-dihydro-1H,1′H-[2,2-biinden]-2-yl)methyl)benzoate [7,8], has been
shown to have a therapeutic effect in two different well-established preclinical models of murine colitis:
the acute dextran sodium sulphate model and the chronic and spontaneous Interleukin-10 (IL-10−/−)
knock-out mouse model. This is indicative that PH46A has therapeutic effect which is independent of
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model specific aetiology [7]. Thus, PH46A has been developed in the clinic for the treatment of IBD
and it has recently completed a Phase I clinical trial study [9].
The original synthetic route to PH46A involves conventional organic chemistry and enantiomeric
separation achieved by preparative chiral HPLC (Scheme 1). The overall yield of the original synthetic
method was considered to be less satisfactory due to the generation of an undesirable diastereoisomer
hydroxyl ester racemic (rac)-6 at ~48% yield and the unwanted enantiomer (R,R)-7 at almost 50%
isolation yield from its racemic mixture (rac)-7 [7]. The ketone reduction step (Step III) was subsequently
optimised by the use of triisobutylaluminum (TiBA) affording the desired product, diastereoisomer
(rac)-6, in a good diastereoselectivity percentage (93%) [10]. Such a highly selective method has
successfully been employed on multi-kilo scale in a GMP environment. However, it is recognised
that the introduction of enantioselective approaches to the synthesis of PH46A would eliminate or
reduce the cost burdens of generating the undesired enantiomer (R,R)-7 and of carrying out a large
scale separation of the enantiomers.
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Scheme 1. The current synthetic scheme of manufacturing PH46A [7,10]. Reagnets and Conditions:
(I) trimethylsilyl trifluoromethanesulfonate, TEA, DCM, −70 ◦C to −75 ◦C, 3 h; (II) methyl
4-(bromomethyl)benzoate, potassium t-butoxide, MtBE, t-BuOH, room temperature, 3 h; (III)
triisobutylaluminium (1.1 M) solution in toluene, toluene,−12 ◦C to 10 ◦C, 2 h; (IV) 30% NaOH, MeOH,
reflux, 24 h; (V) chiral separation by simulated moving bed technology; (VI) N-methyl-D-glucamine,
EtOH, water, 55 ◦C, 5 h.
Two ap roac es to the optimisati n of the PH46A synthesis were investigated and are presented
in this paper. Th first approach involved the inve tigati n of an enantioselective synthesis of the
inte mediate keto m th (Me)-est r (S)-4. In this approach the chiral phase transfer catalyst-promoted
(PTC) benzylation of ke one 3 (or preferably unsaturated ketone 9, to simplify the analysis) was
identified as a particularly promising approach (Scheme 2a). Chiral alkylation using cinchona
alkaloid-derived PTCs has received significant attention from an industrial perspective (largely in
the synthesis of a ino acids), as the conditions required are typically mild, without the requirement
of exclusion of moisture or oxygen, and the catalysts are normally trivial to prepare from the parent
alkaloid. The alkaloids themselves are also readily available. Of particular interest, reports from
Merck [11] and Hughes et al. [12], show that 94% enantioselectivity could be achieved in alkylation
using N-benzylcinchoninium-based catalysts in a system both chemically and sterically related to
our case. This example suggested that a similar cinchonine-derived catalyst would give the desired
enantiomer of (Me)-ester (S)-4, when applied to our system. However, this particular catalyst may
not be suitable as the Merck researchers attributed selectivity to a pi-stacking effect between the
phenyl substituent of the substrate and the benzylic group in the catalyst; such an effect would be
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different in the extended pi-system present in deprotonated unsaturated ketone 9. As a result, an initial
catalyst screen employing four cinchonine-derived catalysts under each of four reactions was planned,
followed by expansion of hits in more depth. Following benzylation to give enantio-enriched (S)-4,
diastereoselective reduction by TiBA can be applied to afford the final desired (S,S)-4.
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Scheme 2. (a) Synthesis of (S)-4 via proposed enantioselective benzylation of ketone 3 or unsaturated
ketone 9; (b) synthesis of (S)-10 via proposed enantioselective biocatalytic hydrolysis of racemate
(R,S)-4.
The second approach investigated th antios lective hydrolysis of (rac)-4 using hydrolase
enzymes while leaving the u favourable ena tiomer (R)-4 unchanged (Scheme 2b). Hydrolase
enzymes have been receiving increasing attention in the context of organic synthesis in the last
decade. As biocatalysts, they provide substrate specificity with high regio- and enantio-selectivity
and they enable the resolution of organic substrates with great efficiency and selectivity [13–15].
Lipases and proteases are the most utilised forms of hydrolytic enzymes, which demonstrate diverse
substrate tolerance, stability in organic solvents and at elevated temperatures [16,17]. Several enzyme
based methods of synthesising chiral alcohols have been developed and employed to date, such
as enzyme-catalysed kinetic resolution of racemic substrates, asymmetric red tion of pro-chiral
keton and asymmetric hydroxylation f hydrocarbons. The scalability (up to 500 g) of some of the
methods are proven [18–20]. It was postulated that if the proposed approach was successful, such
a resolution could furnish the target keto carboxylic acid (S)-10 with the desired ‘S′ configuration
in place. This product could then be isolated and carried through into subsequent steps. It was
envisaged that by screening a panel of 48 hydrolase enzymes against (rac)-4, for the transformation
shown in Scheme 2b, an active and selective enzyme would be identified to afford (S)-10 in high
enantio-purity. As a result, we developed conditions which afforded both high selectivity and high
conversion, and which are described herein.
2. Results and Discussion
2.1. Synthesis of Chiral Standards: (S)-4, (R)-4, (S)-10 and (R)-10
The yntheses of chiral standards, (S)-4, (R)-4, (S)-10 a d (R)-10 were carri out ahead of
performing designed enantiomeric selectivity screening (Scheme 3). The enantiomers (S,S)-7, (R,R)-7,
(R,S)-8 and (S,R)-8 were obtained internally within our group, which were converted to their
corresponding keto (Me)-esters 4 by esterification and oxidation. All reactions proceeded efficiently
and with full conversions to yield (S)-4 and (R)-4. It was found that the reactions with (R,S)-8 and
(S,S)-7 yielded the product with a positive optical rotation value being assigned to be (S)-4, while
(S,R)-8 and (R,R)-7 yielded the opposite enantiomer (R)-4. Following hydrolysis, keto acids (S)-10
and (R)-10 (with positive and negative optical rotation values, respectively) were obtained from their
corresponding (Me)-esters. The enantiomeric excess (e.e.) of each product was also measured and the
results are shown in Scheme 3 and Experimental section. The relevant analytical chromatograms and
spectra are given in Supplementary Materials (Figures S1–S12).
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Table 1. Chiral PTC promoted alkylation of ketone 3 and t-butyl(4-bromomethyl)benzoate.
Entry PTC & Conditions Time e.e. (Major Enantiomer a)
1A N-Bn-quininium chloride, TOL:25% aq. NaOH (5:1) <2 h 11% (S)
1B N-Bn-cinchonidinium chloride, TOL:25% aq. NaOH (5:1) <2 h 12% (S)
1C N-(2-MeO-Bn)-quinidinium bromide, TOL:25% aq. NaOH (5:1) <2 h 12% (R)
1D N-(2-NO2-Bn)-quinidinium bromide, TOL:25% aq. NaOH (5:1) 6 < t < 20 h 24% (R)
1E N,N′-Me2-ephedrinium bromide, TOL:25% aq. NaOH (5:1) 2 < t < 6 h 4% (R) b
1F N-Bn-N′-Me-ephedrinium bromide, TOL:25% aq. NaOH (5:1) 2 < t < 6 h 12% (S)
2A N-(2-NO2-Bn)-quinidinium bromide, TOL/25% aq. NaOH (5:1) <16 h RT 22% (R)
2B N-(2-NO2-Bn)-quinidinium bromide, TOL/12% aq. NaOH (5:1) <16 h RT 25% (R)
2C N-(2-NO2-Bn)-quinidinium bromide, TOL/6% aq. NaOH (5:1) <16 h RT 25% (R)
2D N-(2-NO2-Bn)-quinidinium bromide, TOL/25% aq. K2CO3 (5:1) 16 h RT + <6 h 70 ◦C 34% (R) c
2E N-(2-NO2-Bn)-quinidinium bromide, TOL/6% aq. KOH (5:1) <16 h RT 23% (R)
2F N-(2-NO2-Bn)-quinidinium bromide, THF/MtBE (1:1)/25% aq. NaOH <16 h RT No expected product
2G N-(2-NO2-Bn)-quinidinium bromide, DCM/25% aq. NaOH (5:1) <16 h RT 9% (S)
2H N-(2-NO2-Bn)-quinidinium bromide, THF/solid NaOH (1:50, v:w) <16 h RT No expected product
2I N-(2-NO2-Bn)-quinidinium bromide, MtBE/25% aq. NaOH (5:1) <16 h RT 14% (R)
2J N-(2-NO2-Bn)-quinidinium bromide, TOL/CyH (1:1), 25% aq. NaOH <16 h RT 19% (R)
2K N-(2-NO2-Bn)-quinidinium bromide, TOL/25% aq. Cs2CO3 (5:1) >3 h 60 ◦C 30% (R) d
Conditions: 0.50 mmol each reactant & 20 mg PTC (Entries 1A–F:); 0.25 mmol each reactant & 10 mg PTC (Entries 2A–K). a S & R refer to the configuration of enantiomers eluted on the
chiral IC column. b Within the likely margin of error for e.e. determination. c Ketone 3 conversion >90% by area after heating. d e.e. measured at ~30% ketone 3 conversion by area.
TOL: toluene. e.e.: enantiomeric excess.
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The details of the PTCs preparation are described in the Supplementary Materials. Most of
the screening reactions were quite rapid (Table 1). However, enantioselectivity was lower than
envisaged. Interestingly, Entry 1D was much slower than the others, nevertheless, it gave slightly
higher enantioselectivity. The reaction rate with this particular catalyst relative to others in this small
set cannot be readily correlated to selectivity, as the slower reaction in this case could simply be due to
increased water solubility of the catalyst/base ion pair due to the nitro group. Subsequent investigation
with the N-(2-NO2-Bn)-quinidinium bromide catalyst under a variety of conditions failed to identify
any significant improvements (Entries 2A–K). Indeed, Entry 2G in dichloromethane (DCM) gave the
unwanted (S)-enantiomer (with poor selectivity), while Entries 2F and 2H gave complex HPLC profiles
without any of the desired product.
Based on the most efficient reaction time observed in Table 1, the aq. NaOH/toluene solvent/base
system with t-butyl ester alkylating agent was used to screen a further dozen catalysts covering a wider
range of benzylic substituents (e.g., 2-CN-Bn and anthracenyl) and O-allyl derivatives. The reaction
conditions were kept consistent. Unfortunately, the effects observed for the cinchona alkaloid-based
catalysts could not be fully rationalised (Entries 3G to 3R in Table 2).
Table 2. PTC Reactions using a Range of Catalysts.
Entry PTC Core -CH2Ar -OR′ X− Time
e.e. (Major
Enantiomer a)
3G Cinchonine -CH2(2-NO2-Ph) -OH Br− >16 h b 32% (R)
3H Cinchonine -CH2(2-MeO-Ph) -OH Br− <16 h 28% (R)
3I Cinchonine -CH2(2-CN-Ph) -OH Br− <16 h 15% (R)
3J Cinchonine -CH2(1-Np) -OH Cl− <16 h 27% (R)
3K Cinchonine -CH2(8-Me-1-Np) -OH Cl− <16 h 42% (R)
3L Quinidine -CH2(2-CN-Ph) -OH Br− <16 h 4% (R)
3M Quinidine -CH2(1-Np) -OH Cl− <16 h 33% (R)
3N Quinidine -CH2(2,4-Cl2-Ph) -OH Br− <16 h 7% (R)
3O Quinidine -CH2(2-Pyr) -OH Cl− <16 h 18% (S)
3P Cinchonidine -CH2Ph -O-allyl Br− <16 h 13% (S)
3Q Cinchonidine -CH2(9-anthryl) -O-allyl Br− >16 h b 7% (S)
3R Cinchonidine -CH2(9-anthryl) -OH Cl− <16 h 41% (S)
4S Quinine -CH2(3,5-di(tBu)-Ph) -OH Br− <16 h 3% (S)
4T Cinchonidine -CH2(3,5-di(tBu)-Ph) -OH Br− <16 h 11% (S)
4U Quinine -CH2C(O)(2-NO2-Ph) -OH Br− ~16 h 33% (S)
4V Cinchonidine -CH2C(O)(2-NO2-Ph) -OH Br− >>16 h c 23% (S)
4W Quinine -CH2(3,5-alkaloid+-Ph) d -OH Br− ~16 h 9% (S)
4X Cinchonidine -CH2(3,5-alkaloid+-Ph) d -OH Br− <16 h 12% (S)
4Y Quinine -CH2(4-tBuO2C-Ph) e -OH Br− >16 h 26% (S)
4Z Cinchonidine -CH2(4-tBuO2C-Ph) e -OH Br− <16 h 35% (S)
5K Cinchonine -CH2(8-Me-1-Np) -OH Cl− >16 h 46% (R)
5R Cinchonidine -CH2(9-anthryl) -OH Br− >16 h 38% (S)
Conditions: catalysts at 0.50 or 0.25 mmol scale, PTC (40 mg/mmol, except 14W & 14X at 100 mg/mmol), toluene
(10 mL/mol), 25% aq. NaOH (2 mL/mmol) at room temperature. t-butyl ester alkylating agent was used in all
reactions, except Entries 5K & 5R used methyl ester alkylating agent. a R or S refers to the configuration of the major
enantiomer eluted on the chiral IC column. b <10% ketone 3 by area at 16 h. c Conversion <<50%. d Trimeric PTC.
e Presumed species formed in situ.
For instance, comparison of Entries 3Q and 3R showed that the O-allyl substituent had a strong
impact upon the e.e., yet the results of a similar comparison between Entries 1B and 3P showed
no significant effect. Elucidating the effect of the substituent on the quinoline ring was similarly
difficult, e.g., comparing Entries 1A and 1B (~no difference) or Entries 3I with 3L (large difference).
However, there seemed to be a definite trend in terms of the steric bulk of the -CH2Ar group at
this stage. In particular, Entries 3K and 3R, where the very largest groups were used, showed
promising enantioselectivity.
As a result, preparation of super-bulky PTCs was planned for further investigation (Scheme 5).
The work commenced with quinine, followed by cinchonidine. Disappointingly, many of the alkylating
agents bearing α-branched or neopentylic groups were very unreactive under both the standard
conditions employed [refluxing tetrahydrofuran (THF)) and under more forcing conditions[catalytic
sodium iodide, dimethylformamide (DMF), 120 ◦C, over 48 h]. A few successful reactions were
Molecules 2018, 23, 1503 7 of 18
conducted to afford a small set of bulkier PTCs including two literature PTCs, a trimeric PTC
made using 1,3,5-tris-(bromomethyl)benzene [32] and acetophenone-substituted PTCs made using
2-bromo-2′-nitroacetophenone [33]. These latter PTCs may form a stabilised nitrogen ylide as the
active base, given the acidity of the protons of the acetophenone substituent. Whether this would have
any effect, however, was unclear.
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In parallel, since the catalyst were typically formed fro the alkaloid and a benzylic halide
derivative, several novel catalysts were made from the reaction mixture of TBBMB alkylating agent
and the parent alkaloid. All new catalysts were tested (Entries 4 in Table 2), however, none of these
catalysts performed better than the existing ones, although Entries 4U and 4Z were comparable.
Overall, few conclusions can be drawn from these results. Interestingly, the catalyst formed in situ
using cincho idine proved moderately s lective (Entry 4Z), despite he absence of a bulky substituent
in the 2- or 3-position of the aromatic ring. While not quite as selective as others, the ease of use
(adding only a cheap alkaloid to the reaction mixture) was certainly attractive.
Chiral PTC-promoted alkylations using the analogous (Me)-ester alkylating agent, such as MBMB,
were subsequently investigated. The results in Entries 2D and 2K using weaker carbonate bases
suggested (Me)-ester alkylating agent might b compatible with th se mil er PTC c ditions. A small
set of reactions using N-(2-NO2-Bn)-quinidinium bromide (K2CO3 as base) wer explored. In parallel,
the benzylic chloride electrophile was also tested. MBMB was sufficiently stable under these reaction
conditions to afford the desired (Me)-ester 4. However, as expected, the reaction was slow even at 60 ◦C
and after heating for 3 h it reached only ~35% (area) conversion. The measured e.e. after extended
heating (~14 h, 60 ◦C) was 18% of major enantiomer with R configuration (compared with 30% for the
t-Bu an logue under t e sam conditions). M anwhile, under the sam onditions, the reaction with
analogous methyl(4-chloromethyl)benzoate was too slow to be explored further, giving only a trace
of product. Prolonged heating resulted in the generation of significant impurities. Two reactions,
5K & 5R in Table 2, were set up on 5 mmol scale using the same catalysts as in Entries 3K and 3R,
but with (Me)-ester alkylating agent instead. Despite both reactions being slow, they eventually
reached >95% conversion of ketone 3 after ~2 days, with Entry 5R completing first. The e.e. measured
was 38% after purification, with the later-eluting (S)-enantiomer being the major, as confirmed by
chiral HPLC analysis against (S)-4 reference standard. A portion of (rac)-4 was carried through the
diastereoselective reduction using TiBA with desired (S)-diastereoisomer (87%) being predominant.
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Subsequent hydrolysis afforded a mixture consisting primarily of desired diastereoisomer [(S,S)-7
at 6.2 min & (R,R)-7 at 5.9 min] as confirmed by chiral HPLC against the reference standards. This
therefore demonstrated that the choice of PTC should be cinchonidine or quinine derived.
Thus far, the catalysts with a free -OH group or substituted with an allyl group have been
described. However, it was quite possible that the -OH group of unsubstituted PTCs could be
functionalised during the reaction by the reactive alkylating agent used. This could lead to either
a more selective or a less selective catalyst, or perhaps both could operate in tandem. At least one
literature study has demonstrated facile O-alkylation of a cinchona alkaloid-derived PTC under
similar conditions [34]. Despite this, most authors continue to describe the catalyst as the -OH form.
Indeed a recent paper [35] included a mechanistic explanation based upon H-bonding with this group,
although this explanation seemed to go against the general consensus that it was the cationic N+ that
interacts with the enolate [36].
2.3. PTC-Promoted Alkylation of Unsaturated Ketone 9
Chiral analysis of the achiral PTC reaction of ketone 3 with TBBMB proved complex due to the
presence of impurities eluting close to the peaks of interest (this was not a problem when analysing
the analogous reactions using MBMB, whose products eluted later on the chiral column). It was
thought the formation of the unsaturated ketone 9 under basic conditions could account for one of
the side-products observed. As a result, it was decided to expand the investigation to the ketone 9
and PTC alkylation of such ketone. Unsaturated ketone 9 was made in moderate yield 73% according
to the published method [37], using ketone 3 in a mixture of methanol (MeOH)/DCM with catalytic
trifluoromethanesulfonic acid under reflux conditions. The synthesis of ketone 9 had a further, perhaps
more important driver. Previous reactions gave only suggestions as to whether the enolate that reacts
with the alkylating agent in PTC reactions was derived from ketone 3, or if unsaturated ketone 9 was
formed in situ and was then deprotonated (Scheme 6).
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In fact, either or both routes were possible and it would be challenging to distinguish between
these unless intermediates could be isolated. Indeed, the degr e to which eit er route operates could
also depend h vily upo catalys struct re, which could be one reason why it was difficult t identify
clear trends in selectivity as a function of catalyst structure. Since unsaturated ketone 9 would form
an extended and near-planar, highly conjugated enolate while ketone 3 would not, substrate-catalyst
interactions could be quite different for each of the two pathways. Alkylation of ketone 9 was tested
using TBBMB. The HPLC profiles showed similar results to those of ketone 3, but with slightly fewer
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impurities (Table 3). Most importantly, a clear improvement was shown with at least 3 out of 4 catalysts
when compared to the reactions of ketone 3 under the same conditions.
Table 3. PTC Reactions of Unsaturated Ketone 9.
Entry PTC Core -CH2Ar -OR′
e.e. (Major
Enantiomer a) X
− Reference e.e. of
Reaction of Ketone 3
6D Quinidine -CH2(2-NO2-Ph) -OH 28% (R) Br− 24% (R), 1D
6K Cinchonine -CH2(8-Me-1-Np) -OH 50% (R) Cl− 42% (R), 3K
6R Cinchonidine -CH2(9-anthryl) -OH 50% (S) Cl− 41% (S), 3R
6Z Cinchonidine -CH2(4-tBuO2C-Ph)b -OH 43% (S) Br− 35% (S), 4Z
Conditions: PTC 40 mg/mmol, selected catalysts 0.25 mmol scale, toluene 10 mL/mmol, 25% aq. NaOH
10 mL/mmol, RT, 21 h. a R or S refers to the configuration of the major enantiomer eluted on chiral IC column.
b Presumed species formed in situ.
In each case, HPLC analysis was performed after 3 h and 21 h showing very little reaction progress
after the initial 3 h. The level of both starting materials in Entries 6K, 6R and 6Z were <10% (by area),
but the level in Entry 6D was higher (15–20% by area); dissolution of unsaturated ketone 10 also took
noticeably longer (>2 h) in this reaction. This suggested that the reaction stalled before completion,
possibly due to catalyst decomposition, derivatisation or a change in solubility profile. As with other
reactions, precipitation of solids was observed, but these were not further identified.
In the original control reaction with ketone 3 alone under achiral phase transfer conditions, much
of the starting material remained following overnight reaction, while the achiral PTC alkylation of
ketone 3 was rapid [10]. This demonstrated that the conversion from ketone 3 to unsaturated ketone 9
under the reaction conditions was not facile, or that the elimination was readily reversible. The results
suggested that alkylation takes place via 3-enolate or through both pathways. In contrast, only a
single pathway is possible with unsaturated ketone 9. These results suggested that higher selectivity
might be possible with this new substrate, while the absence of any ambiguity regarding the reaction
pathway could make optimisation more straightforward. The substrate may also be more reactive (it
should have a lower pKa than ketone 3 due to the extended conjugation, which could be important if
deprotonation is rate-limiting), giving a wider scope for variation of base and temperature for future
screening. In addition, it is likely that slight modifications to the synthetic method used to prepare
ketone 3 could be made to afford this unsaturated ketone 9. Given the lower solubility of 9 compared
to 3, product isolation might even be made easier, or isolated yields higher.
2.4. Hydrolase Screening
Enzyme catalysed kinetic bio-resolution is largely used in organic and medicinal chemistry,
especially in the highly controlled enantiomeric synthesis of chiral carboxylic acids [38–42]. Due
to the chirality of the active site of the enzyme, one enantiomer fits better than its counterpart and
therefore converts at a higher rate. As a result, a kinetic resolution of the racemate is achieved [43,44].
For high selectivity, the large difference in the reaction rates of the individual enantiomers should be
achieved [45]. However, in many cases, the resolution does not show such differences in rates. In 1982,
C. J. Sih [46] introduced a useful treatment of the kinetics of enzymatic resolutions, describing the
dependency of the enantiomeric excess of substrate (eeS) and product (eeP) and the reaction conversion
based on a theoretical basis laid by Sharpless [47] and Fajans [48]. Enantiomeric ratio (E), a selectivity
parameter of a resolution, was introduced, which remains constant throughout the reaction and is only
determined by the environment of the system. This method was further developed in the 1990s [49,50].
The relationship between the selectivity of a reaction (E value) and the optical purity of both substrate
(eeS) and product (eeP) was expressed in the following equation:
E =
ln [eeP(1−eeS)]
(eeP+eeS)
ln [eeP(1+eeS)]
(eeP+eeS)
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The expected optical purity of a substrate can be calculated for a chosen point of conversion and
the E value can be determined as a convenient constant value for the “selectivity” of the resolution.
It has well been accepted that E-values of <8 is not a useful resolution; ~8–30 is regarded to yield e.e.
from moderate to good; >30–100 is regarded to yield e.e. from good to excellent; >100 is regarded to
yield excellent e.e. of both enantiomers [51].
(Rac)-4 was screened against a panel of 48 commercial hydrolase enzymes in the presence of two
different organic cosolvents, since organic cosolvents strongly influence the activity and/or selectivity
of many enzymes for a given substrate. Hydrolase screening using DMSO as cosolvent resulted in
four positive hits. AH-06 and AH-24 exhibited only trace levels of conversion and no discernible
e.e. was observed in either case. AH-09 and AH-46 however showed some selectivity for the desired
transformation (Table 4).
Table 4. Positive hits for hydrolase screen of (rac)-4 using DMSO as cosolvent.
Entry Hydrolase e.e.(Substrate)
e.e.
(Product)
Major
Enantiomer E Conversion
7 AH-06 N/A N/A Racemic N/A Trace
8 AH-09 3% 20% S 1.5 16%
9 AH-24 N/A N/A S N/A Trace
10 AH-46 46% 46% R 3 17%
e.e.: enantiomeric excess. E: enantiomeric ratio. S or R refers to configuration.
No positive hits were observed for the screen using 2-MeTHF as cosolvent. In an effort to
improve upon the modest enantio-selectivity observed with DMSO, a further extensive solvent
screen was carried out on (rac)-4 with the most promising enzymes: AH-09, AH-24 and AH-46.
Eighteen cosolvent systems were investigated in total, including hexane, pentane, toluene, DMSO,
DMF, diethyl ether, THF, dioxane, 2-MeTHF, methyl tert-butyl ether (MtBE), DCM, chloroform, ethyl
acetate, acetonitrile, ethanol, Isopropanol (IPA), butanol and a reaction with no organic cosolvent
present. Some representative results of these screens after 72 h reaction time are outlined in Table 5.
Table 5. Representative results of cosolvent screens of (rac)-4 with selected enzymes AH-09, AH-24
and AH-46.
Entry Hydrolase Solvent e.e.(Substrate)
e.e.
(Product)
Major
Product E Conversion
11 AH-09 MtBE 1% 2% S <1 3%
12 AH-09 Diethyl ether 2% 28% S 1.8 6%
13 AH-09 Pentane 1% 8% S 1.2 9%
14 AH-09 Hexane 1% 35% S 2.1 5%
15 AH-09 DMSO 3% 20% S 1.5 16%
16 AH-09 DMF - - - - Trace
17 AH-09 Dioxane - - - - Trace
18 AH-46 MtBE 9% 77% R 8.4 10%
19 AH-46 Toluene 6% 73% R 6.8 8%
20 AH-46 Pentane 1% 7% R 1.2 9%
21 AH-46 Hexane 1% 13% R 1.3 9%
22 AH-46 DMSO 9% 46% R 3 17%
23 AH-46 Diethyl ether - - - - Trace
24 AH-46 Dioxane - - - - Trace
25 AH-24 DMSO - - S - Trace
26 AH-24 Ethanol - - - - Trace
27 AH-24 None - - - - Trace
e.e.: enantiomeric excess. E: enantiomeric ratio. S or R refers to configuration.
Significant improvement was achieved in Entries 18 and 19, where MtBE as cosolvent gave the
best result with a selectivity factor of 8.4 (Figure 1). As AH-46 hydrolyses (R)-4 preferentially over its
enantiomer (Table 5), it is possible to isolate (S)-4 with an e.e. of 95% in approximately 35% yield by
driving the reaction to 68% conversion as shown in Scheme 2. It was believed that further optimisation
screening reaction could be performed on the bio-resolution reaction of (rac)-4 using AH-46 with
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MtBE as cosolvent to further polish the E value, which includes a number of parameters, namely,
temperature, concentration, pH, % cosolvent loading, % enzyme loading, % substrate loading, salt
additives and the organic cosolvent:aqueous buffer ratio. These investigations are currently ongoing.
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3. Materials and Methods
3.1. General Information
Chemical reagents, enzymes and solvents were obtained from commercial suppliers and
used without further purification. The hydrolase enzymes were from an Almac screening kit
(Almac, Craigavon, UK). (rac)-4, enantiomeric compounds [(S,S)-7, (R,R)-7, (R,S)-8, (S,R)-8] and
diastereoisomers 5 and 6, were obtained internally within our group.
Proton Nuclear Magnetic Resonance (NMR) spectra were recorded at 27 ◦C on a DPX 400 MHz
spectrometer (Bruker, Coventry, UK) using solvents CDCl3 and referenced relative to residual CDCl3
(δ = 7.26 ppm). Chemical shifts are reported in ppm and coupling constants (J) in Hertz. Carbon NMR
spectra were recorded on the same instruments (100 MHz) with total proton decoupling. NMR spectra
were analysed with Bruker TopSpin 3.5 NMR software (Bruker, Coventry, UK). ESI mass spectra were
acquired using a Micromass LCT-time of flight mass spectrometer (TOF) interfaced to a Waters 2690
HPLC (Waters, Hertfordshire, UK). The instrument was operated in positive or negative mode as
required. EI mass spectra were acquired using a GCT Premier Micromass TOF instrument (Waters,
Hertfordshire, UK). The instrument was operated in positive mode. Chemical Ionisation (CI) mass
spectra were determined using a GCT Premier Micromass mass spectrometer (Waters, Hertfordshire,
UK) in CI mode utilizing methane as the ionisation gas. Flash chromatography was carried out using
silica gel, particle size 0.04–0.063 mm. TLC analysis was performed on precoated 60F254 slides, and
visualised by UV irradiation. Specific optical rotation was measured at 22 ◦C in CHCl3.
Chiral HPLC analyses were conducted on a Thermo Separations Products LC (ThermoFisher,
Paisley, UK) equipped with a binary pump, column oven and variable wavelength detector with
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data processing using ChromQuest software (v5.0, ThermoFisher, Paisley, UK). Solvents (n-heptane,
ethanol and MeOH) and additive trifluoroacetic acid (TFA) were all of HPLC solvent grade. Samples
were prepared at 0.5 mg/mL in the eluent mixture. Chromatographic conditions for PTC reactions:
Daicel Chiralpak IC column (250 × 4.6 mm, 5 µm) was used with isocratic elution with mobile phase
n-heptane:IPA:TFA. 90:10:0.1 (v/v/v) for individual enantiomers of compounds 7 & 8 with 40 min of
run-time; 95:5:0.1 (v/v/v) for (R)-10 & (S)-10 with 40 min of run-time; 86:14:0.1 (v/v/v) for compounds
3 & 11 with 20 min of run-time; flow rate was 1.0 mL/min; column oven & auto-sampler temperatures
are ambient; injection volume was10 µL; injection loop size was 100 µL and detector wavelength was
254 nm. The chiral HPLC chromatograms of (R,R)-7 (RT = 6.1 min), (S,S)-7 (RT = 6.5 min), (R,S)-8 (RT
= 10.0 min), (S,R)-8 (RT = 12.2 min), (R)-4 (RT = 18.5 min), (S)-4 (RT = 35.8 min), (R)-10 (RT = 22.0 min),
(S)-10 (RT = 29.1 min), (E1)-3 (RT = 8.3 min), (E2)-3 (RT = 8.5 min), (E1)-11 (RT = 7.7 min), (E2)-11
(RT = 11.6 min), are shown in Figures S7–S11 in Supplementary Materials.
A separate chiral HPLC method was further developed for hydrolase screening to provide better
separation of (rac)-4 and the enantiomers of (S)-10 and (R)-10 with shorter retention time. Daicel
Chiralpak AD-H column (250 × 4.6 mm, 5 µm) was used. The flow rate was 1.2 mL/min with isocratic
elution with mobile phase: n-heptane:IPA:TFA 80:20:0.1 (v/v/v) and 20 min of run time. The detector
wavelength was 254 nm and column temperature was ambient. The chromatogram was given in
Figure S12 in the Supplementary Materials, showing RT = 10.4 min for (R)-4, RT = 11.6 min for (S)-4,
RT = 15.5 min for (R)-10 and RT = 17.6 min for (S)-10.
3.2. General Producre for the Sysnthesis of Chiral Standards: (S)-4 and (R)-4
The hydroxycarboxylic acid 7 or 8 (1 eq.) was taken up in a mixture of toluene and MeOH
(3:2, v/v) and stirred vigorously. Trimethylsilyldiazomethane (2.0 M in diethyl ether, 2.3 eq.) was
added dropwise from a syringe until the characteristic yellow colour persisted. TLC analysis was
used to confirm complete conversion of the acid. The solvent was removed under reduced pressure
yielding the intermediate methyl ester. The crude hydroxyl ester was used without further purification.
Chromium trioxide (6.0 eq.) was added to a solution of dry pyridine (2.0 eq.) in dry DCM. The resulting
mixture was stirred at room temperature for 15 min and a solution of the crude hydroxyl ester (1.0 eq.)
in dry DCM was added rapidly. After 15 min the mixture was decanted and the remaining solid
was extracted with diethyl ether. The combined organic extracts were washed with 5% aq. NaOH,
5% aq. HCl, 5% aq. NaHCO3 and brine. The organic layer was dried over sodium sulphate and
concentrated under reduced pressure yielding the target keto ester (S)-4 or (R)-4. The details of each
reaction procedure and 1H-NMR spectra of each product are given in the Supplementary Materials
(Figures S1–S4).
3.2.1. Methyl (S)-4-((1′-oxo-1′,3′-dihydro-1H,2′H-[2,2′-biinden]-2′-yl)methyl)benzoate (S)-4
Enantiomeric acid (S,S)-7 (0.20 g) was used to give (S)-4 (0.14 g, 67%) as pale yellow solid.
[α]D +168.9◦ (1 mg in 1 mL of CHCl3); 1H-NMR (400 MHz, CDCl3) δH 3.32–3.61 (m, 6H, 3 × CH2),
3.89 (s, 3H, CH3), 6.74 (s, 1H, C=CH), 7.15–7.30 (m, 5H, Ar-H), 7.36 (t, J = 7.68 Hz, 2H, Ar-H),
7.40 (d, J = 7.17 Hz, 2H, Ar-H), 7.57 (t, J = 7.68 Hz, 1H, Ar-H), 7.75 (d, J = 8.19 Hz, 1H, Ar-H), 7.83
(d, J = 8.71 Hz, 2H, Ar-H); 13C-NMR δC (100 MHz, CDCl3): 37.2 (CH2), 38.4 (CH2), 41.8 (CH2), 51.6
(CH3), 56.7 (quat. C), 120.3 (tert. C), 123.1 (tert. C), 124.2 (tert. C), 124.3 (tert. C), 125.7 (tert. C), 126.0
(tert. C), 127.3 (tert. C), 128.0 (quat. C), 128.2 (tert. C), 2 × 129.0 (2 × tert. C), 2 × 129.6 (2 × tert. C),
134.7 (tert. C), 2 × 142.5 (quat. C), 142.7 (quat. C), 143.7 (quat. C), 148.3 (quat. C), 151.8 (quat. C), 166.5
(COOCH3), 205.2 (C=O). HRMS (+H+): 395.1657 m/z; required 395.1642; C27H23O3. Chiral HPLC:
Chiralpak IC, heptane:IPA:TFA (90:10:0.1, v/v/v), RT 35.8 min, 98.7% e.e.
3.2.2. Methyl (R)-4-((1′-oxo-1′,3′-dihydro-1H,2′H-[2,2′-biinden]-2′-yl)methyl)benzoate (R)-4
Enantiomeric acid (R/R)-7 (0.20 g) was used to give (R)-4 (0.16 g, 76%) as pale yellow solid.
[α]D −167.9◦ (1 mg in 1 mL of CHCl3); 1H-NMR (400 MHz, CDCl3) δH 3.32–3.61 (m, 6H, 3 × CH2),
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3.89 (s, 3H, CH3), 6.74 (s, 1H, C=CH), 7.16–7.30 (m, 5H, Ar-H), 7.36 (t, J = 7.43 Hz, 1H, Ar-H), 7.41
(t, J = 7.82 Hz, 1H, Ar-H), 7.57 (t, J = 7.43 Hz, 1H, Ar-H), 7.75 (d, J = 7.82 Hz, 1H, Ar-H), 7.86
(d, J = 8.60 Hz, 2H, Ar-H); 13C-NMR (100 MHz, CDCl3) δC: 37.2 (CH2), 38.4 (CH2), 41.8 (CH2), 51.6
(CH3), 56.7 (quat. C), 120.3 (tert. C), 123.1 (tert. C), 124.2 (tert. C), 124.3 (tert. C), 125.7 (tert. C), 126.0
(tert. C), 127.3 (tert. C), 128.0 (quat. C), 128.2 (tert. C), 2 × 129.0 (2 × tert. C), 2 × 129.6 (2 × tert. C),
134.7 (tert. C), 2 × 142.5 (quat. C), 142.7 (quat. C), 143.7 (quat. C), 148.3 (quat. C), 151.8 (quat. C), 166.5
(COOCH3), 205.2 (C=O). HRMS (+H+): 395.1649 m/z; required 395.1642; C27H23O3. Chiral HPLC:
Chiralpak IC, heptane:IPA:TFA (90:10:0.1, v/v/v), RT 18.5 min, 98.7% e.e.
3.3. General Producre of Hydrolysis of Chiral Standards: (S)-10 and (R)-10
Aqueous 30% NaOH (8.0 eq.) was added to a stirred solution of the keto (Me)-ester (S)-4 or (R)-4
(1.0 eq.) in MeOH. The resulting mixture was heated at 60 ◦C for 3 h. Water was added and the mixture
was washed with DCM. The aqueous layer was acidified with 10% aq. HCl and extracted with DCM.
The combined organic extracts were washed with brine and dried under reduced pressure yielding
crude keto-acid. Purification by flash chromatography using 1:1 ethyl acetate:cyclohexane as eluent
gave pure corresponding the keto acid (S)-10 or (R)-10. The details of each reaction procedure and 1H
NMR spectra of each product are given in Supplementary Materials (Figures S5 and S6).
3.3.1. (S)-4-((1′-Axo-1′,3′-dihydro-1H,2′H-[2,2′-biinden]-2′-yl)methyl)benzoic acid (S)-10
Methyl ester (S)-4 (0.25 g) was used to give (S)-10 (0.17 g, 71%) as pale yellow solid. [α]D +142.5◦
in CHCl3; 1H-NMR (400 MHz, CDCl3) δH 3.32–3.62 (m, 6H, 3× CH2), 6.74 (s, 1H, C=CH), 7.15–7.30 (m,
5H, Ar-H), 7.36 (t, J = 7.24 Hz, 1H, Ar-H), 7.41 (d, J = 8.30 Hz, 2H, Ar-H), 7.57 (t, J = 7.49 Hz, 1H, Ar-H),
7.75 (d, J = 7.76 Hz, 1H, Ar-H), 7.93 (d, J = 8.12 Hz, 1H, Ar-H); 13C-NMR (100 MHz, CDCl3) δC 37.2
(CH2), 38.4 (CH2), 41.8 (CH2), 56.7 (quat. C), 120.3 (tert. C), 123.1 (tert. C), 124.2 (tert. C), 124.4 (tert.
C), 125.7 (tert. C), 126.0 (tert. C), 127.1 (quat. C), 127.3 (tert. C), 128.3 (tert. C), 2 × 129.6 (2 × tert. C),
2 × 129.7 (2 × tert. C), 134.7 (quat. C), 134.8 (tert. C), 142.6 (quat. C), 143.5 (quat. C), 143.6 (quat. C),
148.2 (quat. C), 151.8 (quat. C), 171.3 (COOH), 205.2 (C=O). HRMS (+Na+): 403.1305 m/z; required
403.1304; C26H20O3Na. Chiral HPLC: Chiralpak IC, heptane:IPA:TFA (95:5:0.1, v/v/v), RT 29.1 min,
98.8% e.e.
3.3.2. (R)-4-((1′-Oxo-1′,3′-dihydro-1H,2′H-[2,2′-biinden]-2′-yl)methyl)benzoic acid (R)-10
(Me)-ester (R)-4 (0.25 g) was used to give (R)-10 (0.15 g, 63%) as white solid. [α]D −121.3◦ in
CHCl3; 1H-NMR (400 MHz, CDCl3) δH 3.32–3.62 (m, 6H, 3 × CH2), 6.74 (s, 1H, C=CH), 7.15–7.31
(m, 5H, Ar-H), 7.36 (t, J = 7.24 Hz, 1H, Ar-H), 7.41 (d, J = 8.30 Hz, 2H, Ar-H), 7.57 (t, J = 7.49 Hz, 1H,
Ar-H), 7.75 (d, J = 7.76 Hz, 1H, Ar-H), 7.93 (d, J = 8.12 Hz, 1H, Ar-H); 13C-NMR (100 MHz, CDCl3)
δC 37.2 (CH2), 38.4 (CH2), 41.8 (CH2), 56.7 (quat. C), 120.3 (tert. C), 123.1 (tert. C), 124.2 (tert. C),
124.4 (tert. C), 125.7 (tert. C), 126.0 (tert. C), 127.1 (quat. C), 127.3 (tert. C), 128.3 (tert. C), 2 × 129.6
(2 × tert. C), 2 × 129.7 (2 × tert. C), 134.7 (quat. C), 134.8 (tert. C), 142.6 (quat. C), 143.5 (quat. C), 143.6
(quat. C), 148.2 (quat. C), 151.8 (quat. C), 171.3 (COOH), 205.2 (C=O). HRMS (-H+): 379.1329 m/z;
required 379.1336; C26H19O3. Chiral HPLC: Chiralpak IC, heptane:IPA:TFA (95:5:0.1, v/v/v), RT 22.0
min, 95.6% e.e.
3.4. General Procedure of Synthesis of PTCs (Cinchona Alkaloids Derived)
The alkaloid (12.3 mmol, 1 eq.) and the appropriate substituted benzylic halide derivative
(12.3 mmol, 1 eq.) were dissolved in THF (40 mL) with addition of a trace of NaI. The mixture was
heated to reflux overnight and then cooled and stirred at ambient temperature for 1 h. In most cases the
product precipitated as an off-white solid, but where this was not the case and the mixture contained
only a small amount of solid or no solid at all, then diethyl ether (20 mL) was added dropwise.
The solid was removed via filtration and washed with THF (50 mL) or ether:THF, (1:1, v/v, 50 mL)
and was dried under reduced pressure at 40 ◦C. Where the solid formed was not a fine powder it was
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then taken up in DCM and this solution was then added dropwise to rapidly stirring ether (100 mL).
This usually gives a finely divided solid that could be filtered and dried. (Note: The cinchonine derived
PTCs are usually very insoluble. The quinidine derived PTCs are often completely soluble at the end
of the reaction.) The di(t-butyl)benzyl PTC was prepared according to the standard procedure above
and was filtered directly from the reaction mixture.
3.5. Representative Procedure for PTC Alkylations Using MBMB (Entry 5R)
The reaction was carried out in a 100 mL Quickfit Erlenmeyer flask heated in an oil bath.
To a stirred solution of ketone 3 (1.39 g, 5.0 mmol), PTC (40 mg/mmol) and MBMB (1.15 g, 5.0 mmol)
in toluene (50 mL) was added 25% aq. K2CO3 (10 mL) at 35 ◦C. The reaction mixture was stirred in
the heating bath overnight; HPLC analysis of toluene phase indicated ~40% e.e., but conversion was
poor. The reaction temperature was then increased to 70 ◦C. After stirring for 7 h at this temperature
(and over a weekend at RT, though it is unlikely that any significant conversion took place during
this time), the peak of ketone 3 was <5% by area. The mixture was diluted with toluene and water,
and the layers separated. The toluene portion was washed twice with dilute aqueous HCl (~1 M),
once with brine, dried over MgSO4, filtered and concentrated under reduced pressure to afford the
crude product. The product was chromatographed using the dry-flash technique on silica with toluene
as eluent to afford (Me)-ester 4 (0.83 g, 38% e.e., 41%) as an oil that solidified on standing. Some
further product was contained in mixed fractions that were not further purified. 1H-NMR (400 MHz,
DMSO-d6) δH 7.72–7.68 (m, 1H), 7.64 (d, J = 7.4 Hz, 1H), 7.53 (d, J = 7.6 Hz, 1H), 7.39 (t, J = 7.2 Hz,
1H), 7.26 (t, J = 8.0 Hz, 2H), 7.18 (t, J = 7.4 Hz, 1H), 7.10 (td, J = 7.4, 1.1 Hz, 1H), 6.74 (s, 1H), 3.56–3.32
(m, 4H; 2 × AB system), 1.49 (s, 5H).
Table 6. Hydrolase enzymes used to screen against (rac)-4.
Code Hydrolase Code Hydrolase
AH-01 Lipase A from Alcaligenes sp. AH-25 Lipase from Rhizopus niveus
AH-02 Lipase B from Alcaligenes sp. AH-26 Protease from Bacillus stearothermophilus
AH-03 Lipase C from Alcaligenes sp. AH-27 Lipase from Aspergillus niger
AH-04 Lipase from Pseudomonas stutzeri AH-28 Lipase from Penicillium roquefort
AH-05 Lipase from Pseudomonas cepacia AH-29 Protease from Aspergillus niger
AH-06 Lipase A from Candida rugosa AH-30 Lipase from Aspergillus oryzae
AH-07 Lipase D from Alcaligenes sp. AH-31 Protease from Aspergillus melleus
AH-08 Lipase E from Alcaligenes sp. AH-32 Lipase from Penicillium camembertii
AH-09 Lipase B from Candida rugosa AH-33 Protease C from Bacillus subtilis
AH-10 Lipase F from Alcaligenes sp. AH-34 Protease B from Aspergillus oryzae
AH-11 Lipase from fungal source AH-35 Lipase from Pseudomonas fluorescens
AH-12 Protease A from Bacillus subtilis AH-36 Lipase A from Burkholderia cepacia
AH-13 Phytase AH-37 Lipase B from Burkholderia cepacia
AH-14 Alkaline protease A AH-38 Lipase A from Rhizomucor miehei
AH-15 Alkaline lipase A AH-39 Lipase from Candida antarctica
AH-16 Lipase from Bromeliaceae sp. AH-40 Lipase from Thermomyces lanuginosus
AH-17 Lipase from Carica papaya AH-41 Protease A from Bacillus sp.
AH-18 Neutral protease A AH-42 Lipase B from Candida Antarctica (liq)
AH-19 Alkaline protease B AH-43 Lipase A from Candida antarctica
AH-20 Acidic protease A AH-44 Protease B from Bacillus sp.
AH-21 Protease A from Aspergillus oryzae AH-45 Lipase from Thermomyces lanuginosus
AH-22 Protease B from Bacillus subtilis AH-46 Lipase C from Rhizomucor miehei
AH-23 Acylase from Aspergillus sp. AH-47 Lipase Porcine Pancrease Type II
AH-24 Lipase B from Candida rugosa AH-48 Ficin
3.6. Hydrolase Screening Conditions
The enzymes employed in the screening are described in Table 6. The general screening conditions
are outlined below. Each reaction mixture contained the following: 3 mg of (rac)-4, 1 mL of KH2PO4
buffer solution (0.1 M, pH = 7), 50 µL of DMSO (cosolvent system 1) or 200 µL of 2-MeTHF (cosolvent
system 2), 5–10 mg of hydrolase enzyme. The reaction mixture was then shaken for 18 h at 30 ◦C.
After stirring overnight, 1 mL of 2-MeTHF was added to each reaction mixture. 150 µL of 10% H3PO4
was used to adjust the pH to ~2. The reaction vessels were shaken for 5 min which resulted in the
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formation of emulsions in some cases. Centrifugation of the biphasic reaction media might be used to
achieve adequate phase separation. TLC analysis was performed using hexane:ethyl actetate (7:3, v/v)
as eluent. 60 µL of aliquots were taken from the organic phase of positive TLC hits and filtered
through MgSO4, which was further washed with 1 mL of 2-MeTHF. The combined organic solvent
was evaporated and the residue was redissolved in the required HPLC solvent mixture and analysed
by chiral HPLC using enantiomers (S)-10 and (R)-10 as reference standards.
4. Conclusions
Based on the recent method development of diastereoselection in the reduction of ketone 4,
the current study aimed to increase the overall yield of PH46A synthesis on multi-kilo scale further by
developing an enantioselective method. The first phase of the work was the investigation of chiral
PTC promoted alkylation of ketone 3. Twenty-six chiral PTCs, mostly derived from cinchona alkaloids,
were tested. An e.e. up to 46% were achieved and it was identified that the required enantiomer for the
synthesis of PH46A with (S,S) configuration was produced by catalysts from quinine or cinchonidine.
Promising e.e. of up to 50% were also achieved even at this early stage using unsaturated ketone 9 as
an alternative substrate, which would appear to be the better substrate for further optimisation work.
In the second phase, 48 hydrolase enzymes were screened against (rac)-4 in the presence of
two cosolvent systems (DMSO and 2-MeTHF). These screens identified two lead hydrolase enzymes
(AH-09 and AH-46) which were further evaluated by extensive cosolvent screening (18 cosolvent
systems) against (rac)-4. Positive results were obtained yielding suitable reaction conditions of enzyme
AH-46 with MtBE cosolvent providing an observed selectivity factor of 8.4 with an e.e. of 77% for
(R)-10, which could afford unreacted and desired (S)-4 in isolation with higher e.e. up to 95%. Studies
to enhance the enantioselectivity of both chiral PTC alkylation and enzymatic hydrolysis approaches
are currently ongoing. If successful, we believe that the enantioselective method will increase the
overall yield of PH46A and could reduce overall manufacturing cost up to 25%, especially the costly
simulated moving bed chromatography purification step will no longer be required.
Supplementary Materials: Supplementary materials (the detailed experimental procedures for the syntheses
of the chiral reference molecules and their corresponding NMR spectra and HPLC chromatograms) are
available online.
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